RxDoctor Payments DataLook up a doctor →

Zubair Ahmed, MD

Interventional Cardiology · Fayetteville, ARNPI 1831386556

Payments from drug & device makers

$36,419in general payments, 2019–2025

Across 737 payments — averaging $49.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Siemens Medical Solutions USA, Inc.$13K
  • Medtronic$7K
  • Abbott$6K
  • Penumbra, Inc.$3K
  • Abiomed$1K
  • Philips North America LLC$820
  • plus $6K from 34 others

What the payments were for

  • Travel & lodging$18,63551%
  • Food & beverage$17,74449%
  • Education$410%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$36,419 in reported general payments places this provider in the 90th percentile of 89 interventional cardiology providers in Arkansas.

See all interventional cardiology providers in Arkansas

Medicare billing

Part B allowed, 2024
$346,941
Medicare patients
2,249
Services billed
5,867

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban420$420,419
EntrestoSacubitril/Valsartan163$180,535
XareltoRivaroxaban125$123,954
BrilintaTicagrelor64$39,314
FarxigaDapagliflozin Propanediol21$30,922
Repatha SureclickEvolocumab32$28,756
JardianceEmpagliflozin13$18,906
MultaqDronedarone Hcl39$12,058
Repatha SyringeEvolocumab14$8,483
Ranolazine ErRanolazine83$6,007
Dofetilide42$4,494
Atorvastatin Calcium411$3,104
Metoprolol Succinate211$2,763
Isosorbide Mononitrate ErIsosorbide Mononitrate230$2,457
Diltiazem 24hr Er (Cd)Diltiazem Hcl130$2,209

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$659$420,419420 claims
NovartisEntresto$524$180,535163 claims
Johnson & JohnsonXarelto$216$123,954125 claims
AstraZenecaBrilinta, Farxiga$120$70,23785 claims
Boehringer IngelheimJardiance$47$18,90613 claims
Sanofi-aventis U.S. LLCMultaq$46$12,05839 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 89 interventional cardiology providers in Arkansas.

Other interventional cardiology in Fayetteville

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →